Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
2 Mar, 2021 | 01:24h | UTCPhase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The tubulin polymerization and Src kinase inhibitor tirbanibulin was superior to placebo ointment in clearing actinic keratoses on the face and scalp at 2 months. As is typical of the disorder, lesions recurred in 47% of patients at 1 year.
— NEJM (@NEJM) February 17, 2021